Navigation Links
LNA-Based RNA oligonucleotides Potently Inhibit Cancer microRNAs
Date:4/20/2009

COPENHAGEN, April 20 /PRNewswire/ -- Santaris Pharma announced today promising findings on the in vitro and in vivo activity of microRNA-targeted therapeutics against cancer developed on the basis of its proprietary Locked Nucleic Acid (LNA) Drug Platform. In both in vitro and in vivo models Santaris Pharma's cancer targeted LNA-antimiR(R)'s demonstrated outstanding recognition and inhibition of disease-associated microRNAs due to their high specificity and affinity. The findings were presented this week at the AACR Meeting in Colorado at a symposium on microRNAs and human cancer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

"Santaris Pharma has made significant progress in advancing a rich pipeline of clinical and preclinical drug candidates targeting disease related RNAs, including microRNAs," said Henrik 0rum, Santaris Pharma's Chief Scientific Officer. "These results are another demonstration of the fact that our small, single-stranded oligonucleotides have great potential in relation to the development of microRNA targeting therapeutics within a range of disease areas."

Santaris Pharma is a leader within microRNA research and is collaborating with scientists world-wide to exploit the advantages of the LNA chemistry to design and develop effective and safe antimiRs against a broad range of diseases, including cancer.

Santaris Pharma (founded in 2003) is a privately held clinical stage biopharmaceutical company developing new classes of RNA medicines targeting disease-related mRNAs and miRNAs based on its proprietary LNA chemistry. The Company's own research and development activities focus on microRNAs, infectious diseases and metabolic disorders. Santaris Pharma is leveraging its highly effective and efficient Drug Discovery Engine to generate lead LNA drug candidates against a broad array of disease targets selected by strategic partners. The Company and its corporate partners currently have four compounds in clinical development and a full pipeline in late preclinical development. Santaris Pharma has since its inception raised nearly $100 million through private financing and up-front payments.

    For further information please contact
    Randi Krogsgaard, Director, Corporate Communications
    Direct phone +45-4517-9879
    Cell: +45-20488384
    E-mail: rmk@santaris.com
   http://www.santaris.com


'/>"/>
SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference
2. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. TauTaTis Discovers Potent Inhibitor of Parkinsons Disease Gene Activity
5. Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor
6. AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences
7. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
8. Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice
9. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
10. Presentation on Cytopias JAK2 Inhibitor Program in Myeloproliferative Disorders
11. Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... ... DuPont Industrial Biosciences (DuPont) and Archer Daniels Midland Company ... Platts Global Energy for their platform technology to produce a revolutionary biobased ... Platts Global Energy Awards, held in New York on Thursday, Dec. 8. , ...
(Date:12/9/2016)... , Dec. 9, 2016 /PRNewswire/ - Portage Biotech Inc. ... PBT.U), is pleased to announce that Biohaven has issued ... New Haven, Connecticut (PRWEB) Dec 9, 2016 ... "Biohaven") announced today that the U.S. Food and Drug ... request covering its drug candidate BHV-0223, an orally dissolving ...
(Date:12/8/2016)... Medical Incorporated ("OncoSec") (NASDAQ: ONCS ), ... announced financial results for the fiscal first quarter ... our commitment to address an unmet medical need ... with the early clinical response data presented from ... on advancing our lead program – ImmunoPulse® IL-12 ...
(Date:12/8/2016)... MOINES, Iowa , Dec. 8, 2016 Eurofins announces ... US Food and President of Eurofins Scientific Inc. (ESI). ... Division with his proven professional and entrepreneurial experience in leading international ... in the US food testing market to uphold Eurofins, status as ... ...
Breaking Biology Technology:
(Date:12/6/2016)... , Dec. 6, 2016 Valencell , the ... it has seen a third consecutive year of triple ... technology in 2016 with a 360 percent increase in ... This increase was driven by sales of its wrist ... interest in its technology for hearables for fitness and ...
(Date:11/30/2016)... and WARSAW, Poland , Nov. 30, 2016 Not many ... of the most crucial aspects of recovery so we need to do it well. ... risks, including heart problems, high blood pressure, stroke, diabetes, and even cancer. ... and find a Christmas present that could help them to manage their sleep quality? ... ...
(Date:11/28/2016)... 28, 2016 "The biometric ... 16.79%" The biometric system market is in the ... the near future. The biometric system market is expected ... at a CAGR of 16.79% between 2016 and 2022. ... biometric technology in smartphones, rising use of biometric technology ...
Breaking Biology News(10 mins):